<International Circulation>: Could you speak about treatment for diabetic and non-diabetic patients? How is treatment different or in your opinion， how should treatment be different? 
    Prof. Kjeldsen: It should not be different; it should actually be the same. We’ve shown in ACCOMPLISH， 60% of the study population had hypertension and diabetes and had the same good benefit from the ACE CCB combination as the non-diabetics. Similarly in all these hypertension trials， diabetic subgroup may have more endpoints， but the benefit from new drugs compared to standard treatment is more or less the same then non-diabetics. It is an important messagesince controlling hypertension is the number one issue for diabetics.

    <International Circulation>: What do you think of blood sugar and lipid levels on hypertension in diabetic patients? 
    Prof. Kjeldsen:That is complicated. The effect on hypertension is the effect on lowering blood pressure， but it is important to give statins to control lipids in diabetics. The question in the long-term will be to see how they should control the glucose in diabetic patients. But the trials have not yet been that successful， they have been struggling so far for controlling glucose in diabetes， but over time we may find better ways of doing it.